Leap Therapeutics Inc (LPTX.OQ)
LPTX.OQ on NASDAQ Stock Exchange Global Market
7.11USD
20 Apr 2018
7.11USD
20 Apr 2018
Change (% chg)
$-0.33 (-4.44%)
$-0.33 (-4.44%)
Prev Close
$7.44
$7.44
Open
$7.44
$7.44
Day's High
$7.53
$7.53
Day's Low
$7.06
$7.06
Volume
16,390
16,390
Avg. Vol
20,634
20,634
52-wk High
$10.25
$10.25
52-wk Low
$4.94
$4.94
Consensus Recommendations
Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
---|---|---|---|
Outperform | -0.60 | December | 22 Apr 2018 |
Analyst Recommendations and Revisions
1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
---|---|---|---|---|
(1) BUY | 1 | 1 | 1 | 1 |
(2) OUTPERFORM | 2 | 1 | 1 | 1 |
(3) HOLD | 0 | 0 | 0 | 0 |
(4) UNDERPERFORM | 0 | 0 | 0 | 0 |
(5) SELL | 0 | 0 | 0 | 0 |
No Opinion | 0 | 0 | 0 | 0 |
Mean Rating | 1.67 | 1.50 | 1.50 | 1.50 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
# of Estimates | Mean | High | Low | 1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarter Ending Sep-18 | 2 | 0.00 | 0.00 | 0.00 | 0.00 |
Year Ending Dec-18 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
Year Ending Dec-19 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 3 | -0.60 | -0.41 | -0.90 | -0.80 |
Quarter Ending Sep-18 | 3 | -0.57 | -0.35 | -0.83 | -0.76 |
Year Ending Dec-18 | 3 | -2.37 | -1.59 | -3.44 | -3.10 |
Year Ending Dec-19 | 3 | -2.31 | -1.42 | -3.49 | -2.99 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
---|---|---|---|---|
SALES (in millions) | ||||
Quarter Ending Dec-17 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarter Ending Sep-17 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarter Ending Jun-17 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarter Ending Mar-17 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarter Ending Dec-16 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings (per share) | ||||
Quarter Ending Dec-17 | -0.82 | -0.65 | 0.17 | -20.73 |
Quarter Ending Sep-17 | -0.62 | -0.73 | 0.12 | -18.70 |
Quarter Ending Jun-17 | -0.71 | -0.74 | 0.03 | -4.23 |
Quarter Ending Mar-17 | -1.12 | -1.39 | 0.27 | -24.11 |
Quarter Ending Dec-16 | -0.80 | -0.58 | 0.22 | -27.50 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarter Ending Sep-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Year Ending Dec-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Year Ending Dec-19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | -0.60 | -0.60 | -0.65 | -0.69 | -0.80 |
Quarter Ending Sep-18 | -0.57 | -0.57 | -0.59 | -0.60 | -0.76 |
Year Ending Dec-18 | -2.37 | -2.37 | -2.52 | -2.61 | -3.10 |
Year Ending Dec-19 | -2.31 | -2.27 | -2.39 | -1.67 | -2.99 |
Estimates Revisions Summary
Last Week | Last 4 Weeks | |||
---|---|---|---|---|
Number Of Revisions: | Up | Down | Up | Down |
Revenue | ||||
Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
Year Ending Dec-18 | 0 | 0 | 0 | 0 |
Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings | ||||
Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
Year Ending Dec-18 | 0 | 0 | 0 | 0 |
Year Ending Dec-19 | 0 | 1 | 0 | 1 |
- BRIEF-Leap Therapeutics Files For Mixed Shelf Of Up To $100 Mln
- BRIEF-Leap Therapeutics Reports Qtrly Loss Per Share Of $0.65
- BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy
- BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders
- BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics as of Nov 14